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Abstract 
Background: Noninvasive encapsulated follicular variant of papillary thyroid carcinoma (PTC) 
has recently been reclassified as noninvasive follicular thyroid neoplasm with papillary-like 
nuclear features (NIFTP). Implementation of the new terminology may alter the implied risk of 
malignancy (ROM) across the six categories of The Bethesda System for Reporting Thyroid 
Cytopathology (TBSRTC). Methods: The study cohort consisted of thyroid fine needle 
aspiration (FNA) cases which were assessed between January 2011 and June 2016 and led to  
surgical resections. For each case, patient demographics as well as cytologic and corresponding 
histologic diagnoses were recorded. The surgical specimens diagnosed as follicular variant of 
PTC (FVPTC) were re-reviewed to identify cases that met the diagnostic criteria for NIFTP. The 
ROM with and without exclusion of NIFTP from malignant categorization, as well as the relative 
change in ROM were calculated for individual categories of TBSRTC. Results: A total of 908 
FNA cases with surgical follow-up were retrieved and PTC was identified in 252 (27.8%) 
surgical specimens. Twenty-nine of 252 (11.5%) were initially classified as FVPTC, of which 17 
(6.7%) were reclassified as NIFTP. The cytologic interpretations for the majority of NIFTP cases 
were atypia of undetermined significance/follicular lesion of undetermined significance 
(AUS/FLUS, n=8) or follicular neoplasm/suspicious for neoplasm/(FN/SFN, n=4). Excluding 
NIFTP from malignant categorization resulted in a relative decrease in ROM in AUS/FLUS 
(25.8%) and FN/SFN (22.3%) categories. Conclusion: Our institutional data demonstrates that 
eliminating NIFTP from malignant categorization may result in a reduction of the implied ROM 
for AUS/FLUS and FN/SFN categories.  
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undetermined significance (AUS/FLUS); follicular neoplasm/suspicious for follicular neoplasm 
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Introduction 
Papillary thyroid carcinoma (PTC) is the most common malignant tumor of the thyroid 
worldwide. After conventional PTC, follicular variant PTC (FVPTC) is considered the most 
common variant of PTC. Jung, et al. studied the demographic, clinical, pathologic, and molecular 
characteristics of PTCs diagnosed at the University of Pittsburgh for the period from 1974 to 
2009 and demonstrated an increased incidence of FVPTC, including both encapsulated and 
infiltrative subtypes, represented approximately 25% of all diagnosed PTCs. Furthermore, the 
study noted a sharp increase in detected RAS mutations in PTCs, particularly in tumors with 
follicular growth patterns.(1) 
Recently, the Endocrine Pathology Society working group conducted a retrospective study of 
noninvasive encapsulated FVPTC with the aim of assessing clinical outcomes, refining 
diagnostic criteria, and developing a new terminology that appropriately reflects the biological 
and clinical characteristics of this entity. Based on its very low risk of adverse outcomes, the 
working group concluded that noninvasive encapsulated FVPTC should be reclassified 
as“noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)”, 
eliminating the term carcinoma from the entity.(2)  
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The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) has been widely 
accepted as a standard reporting system for assessing fine needle aspiration (FNA) of thyroid. 
TBSRTC consists of six categories, including non-diagnostic, benign, atypia of undetermined 
significance/follicular lesion of undetermined significance (AUS/FLUS), follicular 
neoplasm/suspicious for follicular neoplasm (FN/SFN), suspicious for malignancy (SFM) and 
malignant. An implied risk of malignancy (ROM) has been assessed and estimated for each of 
the six categories.(3)   
TBSRTC has been implemented in our clinical practice since January 2011. In comparison to the 
pre-TBSRTC period, the adoption of TBSRTC in our institution resulted in a reduced surgical 
rate, particularly for the benign and AUS/FLUS categories. However, the ROM for each of the 
six categories did not differ significantly between the pre- and post-TBSRTC periods. The rate of 
histology-proven malignancy after implementation of TBSRTC was 3.5%, 17.9%, 27.8%, 
75.0%, and 98.0% for benign, AUS/FLUS, FN/SFN, SFM, and malignant categories, 
respectively. These values fall into or close to the ranges of the ROM estimated by TBSRTC 
(0%–3% for benign, 5%–15% for AUS/FLUS, 15%–30% for FN/SFN, 60%–75% for SFM, and 
97%–99% for malignant).(4)  
The current study was conducted to investigate if implementing NIFTP (formerly termed as non-
invasive encapsulated FVPTC) terminology and excluding it from malignant categorization may 
alter the ROM across the six categories of TBSRTC. 
 
Material and Methods 
The retrospective study was approved by the Institutional Review Board (IRB) of the University 
of Michigan. The study cohort consisted of all thyroid FNA cases which were assessed between 
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January 2011 and June 2016, and were subsequently treated with surgical interventions. 
Endocrinologists, radiologists, and surgeons performed palpation- or ultrasound-guided FNAs  
with or without cytopathologist-assisted rapid on-site evaluation (ROSE). Three to six passes 
were collected for each FNA specimen. For FNAs aided with ROSE, two conventional smears 
were made for each pass. One smear was air-dried and stained with Diff-Quik protocol to be 
evaluated immediately for specimen adequacy while the other smear was fixed with Sprayfix
TM
  
and later stained with Papanicolaou stain. The needle was then rinsed in Cytolyt solution for a 
ThinPrep and/or a cell block.  For FNAs without ROSE, all passes were submitted in Cytolyt 
solution from which a ThinPrep and a cell block slide were prepared. All FNA specimens were 
interpreted using TBSRTC.  
For each case, age and gender of the patient, size and location of the nodule, cytologic 
interpretation, and corresponding histologic diagnosis were retrieved and recorded. The histology 
slides from the surgical specimens originally diagnosed as FVPTC were re-reviewed by one 
surgical pathologist (AS) to identify cases that met the diagnostic criteria for NIFTP. Briefly, 
diagnostic criteria for NIFTP include 1) encapsulation or clear demarcation, 2) follicular growth 
pattern (<1% papillae, no psammoma bodies, 30% solid/trabecular/insular growth pattern), 3) 
nuclear score 2-3, 4) no vascular or capsular invasion, 5) no tumor necrosis and 6) no high 
mitotic activity.(2) Each case was assessed using the detailed inclusion and exclusion criteria. 
Both FVPTC with Hurthle cell changes and microcarcinoma (less than 1 cm) were excluded. 
Based on the follow-up histologic diagnosis, the ROM with and without exclusion of NIFTP 
from malignant categorization, as well as the relative change in ROM were calculated for each of 
TBSRTC categories as follows : 
ROM = number of cases with histology-proven malignancy/total number of cases  
Page 5 of 29
John Wiley & Sons
Diagnostic Cytopathology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
Relative change in ROM =100% x [ (ROM with NIFTP - ROM without NIFTP)/ROM with 
NIFTP] 
Z score calculation for two population proportions was used to compare the ROM with versus 
without the exclusion of NIFTP from malignant categorization for each of TBSRTC categories. 
A p-value less than 0.05 was considered to be statistically significant.  
 
Results 
A total of 908 FNA cases with surgical follow-up were retrieved. The corresponding surgical 
specimens revealed malignant neoplasms in 278 (30.6%) cases, among which were 252  PTCs, 
representing 27.8% of the total cohort. The remaining malignant neoplasms included 10 
follicular cell carcinomas, 10 medullary thyroid carcinomas, 5 anaplastic thyroid carcinomas, 
and 1 poorly differentiated thyroid carcinoma. Among the histology-proven PTC cases, 61.1% 
(154/252) and 13.5% (34/252) were cytologically interpretated as positive and suspicious for 
PTC, respectively, on prior cytologic specimens. The remaining PTC cases were classified as 
AUS/FLUS (11.1% ), benign (5.5%), FN/SFN (4.8%) and non-diagnostic (4%) on prior 
cytologic sp cimens (Table 1). 
As can be seen in Table 2, 29 (11.5%) out of 252 PTC cases were initially diagnosed as FVPTC. 
Re-review of these surgical specimens confirmed 17 (6.7%) cases of noninvasive encapsulated 
FVPTC, now reclassified as NIFTP. The majority of these cases were classified as AUS/FLUS 
(47.1%) and FN/SFN (23.5%) on the pre-operative cytologic specimens, while only two (11.8%) 
were interpreted as SFM or malignant. Three (17.6%) of these cases were interpretated as a 
benign nodule on cytology. On re-review of cytologic material, the various degrees of 
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architectural atypia were appreciated while nuclear features of conventional PTC were absent or 
subtle in most of NIFTP cases (Figure 1). 
The 17 cases that were reclassified as NIFTP revealed female predominance, with a female to 
male ratio of 16:1. The ages of patients ranged from 15 to 72 years old. The size of the thyroid 
nodules ranged from 0.8 cm to 4.0 cm. Unifocal disease was detected in 14 cases, while the 
remaining 3 had multifocal disease. Hemithyroidectomy and total thyroidectomy was performed 
in 13 and 4 cases, respectively. Total thyroidectomies were performed for multifocal disease 
involving both lobes (2 cases) or a pre-operative cytologic diagnosis was SFM (1 case) or 
malignant (1 case). None of patients received radioactive iodine therapy. All patients have 
remained disease free during the follow-up period of up to six years.  
Table 3 compares the ROM calculated when NIFTP was excluded from malignant categorization 
with the ROM when NIFTP was considered a malignancy. When NIFTP was excluded from 
malignant caterization, the ROM decreased across all diagnostic categories. The relative 
decrease in ROM was most pronounced in the AUS/FLUS (25.8%) and FN/SFN (22.3%) 
categories. The relative decrease in ROMs was subtle in both SFM (2.8%) and malignant (0.6%) 
categories. Regardless, the p-values (0.42 to 1.0) did not reach statistical significance for any of 
the TBSRTC categories.  
 
Discussions 
The potential alteration of the ROM across the six categories of TBSRTC as a result of excluding 
NIFTP from malignant categorization has become one of the major concerns raised among 
pathologists, as well as endocrinologists and surgeons who treat patients with thyroid nodules.  It 
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is important to stress that the current study is one of a few studies following the landmark 
publication on NIFTP from Endocrine Pathology Society working group. During the re-review 
of the FVPTC surgical specimens in the current study, detailed inclusion and exclusion criteria 
outlined in the landmark manuscript were utilized as a guideline to identify the cases that 
fulfilled the criteria for NIFTP.(2) The current study demonstrates that histology-proven NIFTP 
represented 6.7% (n=17) of 252 cases that were previously classified as PTC. The majority of the 
NIFTP cases on surgical resections were interpreted as AUS/FLUS (47.1%) and FN/SFN 
(23.5%) on pre-operative cytology specimens. When NIFTP was not considered malignant, there 
was a notable relative decrease in ROM for both categories (25.8% and 22.3%). However, the 
difference in ROMs failed to reach statistical significance due to the limited cohort of NIFTP. It 
is noteworthy to mention that the patients with NIFTP were less likely to be overtreated at our 
institution as thyroid nodules with a cytologic diagnosis of AUS/FLUS or FN/SFN are 
commonly managed by hemithyroidectomy rather than total thyroidectomy.  
Table 4 compares our data with the published data of other studies on the relative decrease in 
ROMs across the categories of TBSRTC after excluding noninvasive FVPTC from malignant 
categorization. Briefly, Strickland, et al. studied 655 patients who underwent FNA and 
subsequent surgical resection in a single institution. PTC was identified in 304 (46.4%) patients 
including 85 patients with noninvasive FVPTC, accounting for 23.7% of all PTC cases. 
Excluding noninvasive FVPTC from malignant categorization resulted in the most significant 
relative decrease in ROM (nearly 50%) in the SFM category. Their findings are quite remarkable 
as these patients were treated with a total or near total thyroidectomy rather than 
hemithyroidectomy.(5)  Faquin, et al. studied 756 cases of histology-proven PTCs in institutions 
in the United States and Europe, of which 173 (22.8%) were classified as noninvasive FVPTC. 
Page 8 of 29
John Wiley & Sons
Diagnostic Cytopathology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
Most of the cases classified as noninvasive FVPTC were interpreted as AUS/FLUS (31.2%), 
FN/SFN (26.6%) or SFM (24.3%) on pre-operative cytology. In this study, the  relative decrease 
in ROM was most pronounced in FN/SFN category (45.5%) followed by AUS/FLUS category 
(43.6%)  and SFM category (28.3%).(6) Similarly, a single-institution study by Canberk, et al  
also showed the most significant relative decrease in ROM in the FN/SFN category (66.0%).(7) 
Recently, Layfield, et al analyzed their own institutional data along with these three 
aforementioned studies using a meta-analysis method. They found that re-categorization of 
noninvasive FVPTC or NIFTP as benign entities showed the greatest reduction in ROM in SFM 
and AUS/FLUS categories.(8)  Two of these aforementioned studies (Strickland, et al and  
Faquin, et al) showed a higher percentage of PTC among all surgically treated cases (41.4% and 
46.4%) than our institution (27.8%). In addition, our data revealed a lower proportion (6.7%) of 
NIFTP among all PTCs compared to rate of diagnosis of noninvasive FVPTC in the 
aforementioned studies led by Strickland, Faquin and Cranbrek (23.7% , 22.8% and 27.5%, 
respectively). However, these three studies were conducted prior to the publication of the 
diagnostic criteris for NIFTP by the Endocrine Pathology Society working group. Thus, it 
remains unknown how many of the cases reclassified as benign in these studies actually met the 
current criteria for NIFTP and how application of the criteria would affect the study outcomes.  
It is important to be aware of variations among different institutions with regard to prevalence of 
PTC and NIFTP, as well as diagnostic thresholds for assessing cytologic and/or histologic 
specimens for each diagnostic category. It is crucial for pathologists, endocrinologists, and 
surgeons to have a clear understanding of practice patterns in their own institutions in order to 
provide management appropriate to patients with NIFTP and to avoid overtreatment, i.e. total or 
near total thyroidectomy. 
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Despite rendering pre-operative cytologic diagnoses of SFM or PTC in 2 of 17 NIFTP cases in 
the current study, most cases carried a preoperative diagnosis of AUS/FLUS or FN/SFN.  While 
many of these cases lacked diagnostic features of conventional PTC, others displayed only subtle 
or focal cytologic atypia associated with PTC.  Our findings are similar to another study by 
Ibrahim, et al, who studied 23 NIFTP cases.  The pre-operative FNAs of these 23 cases were 
most commonly categorized into the AUS/FLUS category (61%), followed by FN/SFN (17%). 
One case (4%) was interpreted as suspicious for PTC, but none were interpreted as positive for 
PTC.(9) The phenomena that most NIFTP fall into AUS/FLUS and FN/SFN categories was also 
seen in a study containing 56 NIFTP cases by Brandler, et al.(10) Efforts to investigate if a 
definitive diagnosis of  NIFTP may be established based on cytologic findings alone have been 
attempted. Bizzarro, et al. claimed that NIFTP showed a different microfollicular pattern, 
grooves, and nuclear size compared to follicular adenoma, invasive FVPTC, and conventional 
PTC while no definitive evidence of PTC was identified in NIFTP. They hoped that an 
algorithmic approach to follicular-patterned lesions would improve the diagnostic accuracy of 
NIFTP by FNA.(11) Maletta, et al. found that nuclear features (size, irregular contours, and 
chromatin clearing) seen in NIFTP did not differ significantly from those of invasive FVPTC, 
indicating that NIFTP cannot be reliably diagnosed preoperatively.(12) Given the lack of 
quantitative and qualitative cytologic atypia diagnostic of conventional PTC in NIFTP on 
cytologic specimens in our study and other studies, it’s unlikely to be diagnosed as positive for 
PTC on cytology. However, it seems problematic to differentiate NIFTP from other entities with 
follicular growth pattern, i.e. follicular adenoma/carcinoma and invasive FVPTC.  Overall, 
making a definitive diagnosis of NIFTP  basen on cytologic evaluation alone is a great 
challenge.(10, 13, 14).  
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Over the past several years, molecular tests have been utilized as an adjunct to FNA cytology to 
further categorize the thyroid nodules with indeterminate cytologic diagnoses (AUS/FLUS, SFN, 
SFM) and each has its strengths and limitions.(15) Several studies on molecular profiling of 
NIFTP have been published following the proposal of the new terminology. Accordingly, 
Paulson, et al. found that NIFTP accounted for more than half of RAS-mutant thyroid 
neoplasms.(16) Molecular analysis performed on the surgical specimens of NIFTP and invasive 
FVPTC revealed that NIFTP was primarily associated with mutations in RAS while invasive 
FVPTC cases were associated with BRAFV600E or RAS mutations, indicating a lower likihood 
of accurate distinction between NIFTP and invasive FVPTC by FNA due to the overlpapping 
molecular profiles.(17)  
In summary, our institutional data demonstrates that NIFTP is most likely categorized as 
AUS/FLUS or FN/SFN on pre-operative cytologic evaluation. Eliminating NIFTP from 
malignant categorization may result in a marked reduction of the implied ROM for AUS/FLUS 
and FN/SFN categories. It is important to have a clear understanding of practice patterns in one’s 
own institution in order to provide management appropriate to patient with NIFTP and to avoid 
overtreatment.  
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Legends 
Figure 1. Cytologic categorization of histology-proven noninvasive FVPTC (NIFTP). 
A and B. AUS/FLUS (Diff-Quik stain, 40x and Papnicouluo stain, 600x); 
C and D. FN/SFN (Diff-Quik stain, 100x and Papnicouluo stain, 600x); 
E and F. SFM (Diff-Quik stain, 100x and Papnicouluo stain, 400x); 
G and H. PTC (Diff-Quik stain, 200x and Papnicouluo stain, 400x); 
I and J. noninvasive FVPTC (NIFTP) (H&E 40x and 400x). 
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Table 1. Cytologic-histologic correlation    
TBSRTC 
category Benign 
Histologic 
FA FCA 
Diagnoses 
PTC M (non-PTC) Total 
ND 83 18 1 10 0 112 
Benign 238 17 1 14 0 270 
AUS/FLUS      160 52 0 28 3 243 
FN/SFN 21 29 6 12 0 68 
SFM 6 2 0 34 1 43 
Malignant 3 1 2 154 12 172 
Total 511 119 10 252 16 908 
ND: non-diagnostic; AUS/FLUS: Atypia of undetermined significance/Follicular lesion of 
undetermined significance; FN/SFN: follicular neoplasm/suspicious for follicular neoplasm; 
SFM: suspicious for malignancy; FA: follicular adenoma; FCA: follicular carcinoma; PTC: 
papillary thyroid carcinoma; M: malignant. 
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Table 2. Distribution of histology-proven FVPTC across the diagnostic categories of TBSRTC  
TBSRTC 
 All 
FVPTC 
 Noninvasive 
FVPTC   
                Invasive        
FVPTC   
 
Category    (NIFTP)   
ND        1  0  1  
Benign                  5  3  2  
AUS/FLUS          11  8  3  
FN/SFN  5  4  1  
SFM  1  1  0  
Malignant            6  1  5  
Total 29  17  12  
ND: non-diagnostic; AUS/FLUS: Atypia of undetermined significance/Follicular lesion of 
undetermined significance; FN/SFN: follicular neoplasm/suspicious for follicular neoplasm; 
SFM: suspicious for malignancy; FVPTC: follicular variant of papillary thyroid carcinoma; 
NIFTP: noninvasive follicular thyroid neoplasm with papillary-like nuclear features. 
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Table 3. Comparison of ROMs before and after excluding NIFTP from malignant categorization 
TBSRTC ROM (%) ROM (%) Absolute decrease  Relative decrease 
Category       (before)  (after)   in ROM (%) in ROM(%) 
ND 9.8 9.8 0 0 
Benign 5.6 4.4 1.2 21.4 
AUS/FLUS 12.8 9.5 3.3 25.8 
FN/SFN 26.5 20.6 5.9 22.3 
SFM 81.4 79.1 2.3 2.8 
Malignant 97.7 97.1 0.6 0.6 
NIFTP: noninvasive follicular thyroid neoplasm with papillary-like nuclear features; ND: non-
diagnostic; AUS/FLUS: Atypia of undetermined significance/Follicular lesion of undetermined 
significance; FN/SFN: follicular neoplasm/suspicious for follicular neoplasm; SFM: suspicious 
for malignancy;  
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Table 4. Relative decrease in ROM at different institutions after excluding NIFTP from malignant categorization 
Studies Cases with  Histology-proven cases classified    Relative decreases in ROM (%) across six categories 
  surgical F/U (n) PTC n (%)  as NIFTP ND Benign AUS/FLUS FN/SFN SFM M 
Strickland 655 304 (46.4) 72 (23.7) 10 59 45 18 48 5 
Faquin 1827 756 (41.4) 173(22.8 5.5 37.6 43.6 45.5 28.3 3.3 
Canberk 1886 341 (18.1) 94(27.5) 50 14 33 66 33 11.2 
Layfield 315 - - 0 33.6 13.2 11.3 20.5 12.8 
Current 908 252 (27.8) 17 (6.7) 0 21.4 25.8 22.3 2.8 0.6 
ROM: risk of malignancy; NIFTP: noninvasive follicular thyroid neoplasm with papillary-like nuclear features; ND: non-diagnostic; 
AUS/FLUS: Atypia of undetermined significance/Follicular lesion of undetermined significance; FN/SFN: follicular 
neoplasm/suspicious for follicular neoplasm; SFM: suspicious for malignancy; M: malignant. 
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Figure 1. Cytologic categorization of histology-proven noninvasive FVPTC (NIFTP).  
A and B. AUS/FLUS (Diff-Quik stain, 40x and Papnicouluo stain, 600x);  
C and D. FN/SFN (Diff-Quik stain, 100x and Papnicouluo stain, 600x);  
E and F. SFM (Diff-Quik stain, 100x and Papnicouluo stain, 400x);  
G and H. PTC (Diff-Quik stain, 200x and Papnicouluo stain, 400x);  
I and J. noninvasive FVPTC (NIFTP) (H&E 40x and 400x).  
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